1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

Slides:

Advertisements

Similar presentations

Chronic Productive Cough Dr. Miao Shang Su. Present History - A 5-year-old girl come to your clinic for the first time. Her mother reports that the child.

Advertisements

Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 32 Bronchodilator Drugs and the Treatment of Asthma.

C A SHINKWIN BON SECOURS GP STUDY DAY 28 JANUARY, 2012.

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

ISEE 2007 PREVALENCE STUDY OF ALLERGY DISEASES IN CHILDREN IN THE CZECH REPUBLIC Růžena Kubínová, Center of Environmental Health, National Institute of.

Lesson 4 Care and Problems of the Respiratory System Respiratory system problems can affect the functioning of other body systems. Imagine not being able.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.

Meredith G. Hennon, MPH and the Supercourse team in Pittsburgh.

Drugs For Treating Asthma

BRONCHIAL ASTHMA YOUSEF ABDULLAH AL TURKI MBBS,DPHC,ABFM

Chronic Obstructive Pulmonary Disease Natasha Chowdhury.

COPD MANAGEMENT FALLS SHORT AT RCRMC Jean Solomon, M.D.

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

Lisa Nave Nursing Platt College. Asthma is a chronic inflammatory disease of the lungs characterized by narrowing of the airways in the lungs causing.

1 One Year Post-Exclusivity Adverse Event Review for Tamiflu® (oseltamivir) Pediatric Advisory Committee Meeting November 18, 2005 Melissa M. Truffa, R.Ph.

Respiratory & Medical Critical Care and Paramedic Levels.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

Ozone and Health Deborah M. Drechsler, Ph.D. Sierra Ozone Summit June 4, 2008.

Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)

NYU Medical Grand Rounds Clinical Vignette Lucy Doyle MD, PGY-2 March 24, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.

Lesson 4 Care and Problems of the Respiratory System Respiratory system problems can affect the functioning of other body systems. Imagine not being able.

By Dalia Munoz ASTHMA. is a serious and ongoing disease that affects the airways of both adults and children. Airways are the tubes that carry air in.

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pediatric Exclusivity 1-Year Adverse Event Reporting for Drug Products Containing.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post Exclusivity Adverse Event Review: Topotecan Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

NYU Medical Grand Rounds Clinical Vignette Verity Schaye, MD PGY-3 September 15, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Advanced & Primary Care Paramedic Changes to Medical Directives Fall 2005.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

Focus Area 17: Medical Product Safety Progress Review November 5, 2003.

1 One Year Post Exclusivity Adverse Event Monitoring as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Dr.

Chronic Obstructive Pulmonary Disease Austin Paul K.

Macrolide Antibiotics and Torsade de Pointes Postmarketing Analysis

OTC NSAID and ASA GI Bleeding Analysis of Spontaneous Reports Nonprescription Drugs Advisory Committee Meeting Joyce P. Weaver, Pharm.D. Office of Drug.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Naloxone: Prescribing and Dispensing

1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports Pediatric Advisory Subcommittee of the Anti-Infective Drugs.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Allergic Rhinitis- inflammation of the nasal airways from an allergen (dust, pollen, animal dander). Symptoms runny noseitching eye rednessswelling Treatment-

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.

©2012 Cengage Learning. All Rights Reserved. Chapter 4 Common Chronic Medical Conditions Affecting Children’s Health.

What is the disease? The disease is asthma. Asthma is a chronic lung disease that inflames and narrows the airways. asthma caucuses recurring wheezing,

Department of Pharmacology

Chapter 9 Respiratory Drugs.

BRONCHIAL ASTHMA YOUSEF ABDULLAH AL TURKI MBBS,DPHC,ABFM

Medications for the respiratory system

Drugs Affecting the Respiratory System

Presentation transcript:

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD, BCPS Postmarketing Safety Evaluator Division of Drug Risk Evaluation Center for Drug Evaluation and Research Food and Drug Administration

2 Budesonide

3 Drug Use Trends in Outpatient Settings: Budesonide The total number of prescriptions dispensed for all budesonide products increased from approximately 6.0 million in 2001 to 7.8 million in Pediatric patients (ages 1–16 years) accounted for approximately 29.1% of total U.S. prescriptions of budesonide products dispensed in 2003 ( 2.3 million). 1,2* In 2003, Rhinocort/Rhinocort Aqua was the fourth most commonly dispensed steroid nasal inhalant and the most commonly used budesonide product, accounting for 58.6% (~4.5 million) of budesonide prescriptions. Of these, 17.2% (~774,000) prescriptions were dispensed to pediatric patients. 1,2* IMS Health, National Prescription Audit Plus , On-Line, Dec 2000 – Nov 2003, Data Extracted Feb 2004 AdvancePCS  Dimension Rx, On-Line, Dec 2000 – Nov 2003, Data Extracted Feb 2004 *Calculation based on application of proportions of pediatric budesonide prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of budesonide prescriptions dispensed nationwide to pediatric population.

4 Drug Use Trends in Outpatient Settings: Budesonide Pulmicort represented 39.6% (~3.1 million) of budesonide prescriptions in Of these 3.1 million prescriptions, 58% were dispensed to pediatric patients. 1,2* Entocort represented 1.8% (141,000) of budesonide prescriptions in Of these 141,000 prescriptions, 3.9% were dispensed to pediatric patients. 1,2* IMS Health, National Prescription Audit Plus , On-Line, Dec 2000 – Nov 2003, Data Extracted Feb 2004 AdvancePCS  Dimension Rx, On-Line, Dec 2000 – Nov 2003, Data Extracted Feb 2004 *Calculation based on application of proportions of pediatric budesonide prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of budesonide prescriptions dispensed nationwide to pediatric population.

5 Adverse Event Reports: Budesonide From Marketing Approval (2/14/94 – 12/12/03): –Total number of reports, all ages: 2845 reports (1284 US) From One-year Post Exclusivity (11/12/02 – 12/12/03): –Total number of reports, all ages: 157 (68 US) –100 serious (26 US) –Pediatric reports: 38 (24 US) –22 serious (7 US) –1 death (US)

6 Pediatric Adverse Events: Budesonide 11/12/02 – 12/12/03 (n=38) Gender –Female 13 –Male 22 –Unknown 3 Age –0 - <1 mo.2 –1 mo. - <2 yrs7 –2 - 5 yrs 15 – yrs7 – yrs7 – Products* –Pulmicort27 –Rhinocort5 –Entocort1 –Unspecified product5 *in some cases product used was non-US brand

7 Pediatric Adverse Events*: Budesonide (n=38) Convulsions-6 Asthma Nos-5 Growth retardation-4 Blood Cortisol Decreased-3 Condition Aggravated-3 Adrenal Suppression-2 Anaphylactic Reaction-2 Cataract Bilateral Nos-2 Cushing’s Syndrome-2 Cushingoid-2 * Each case can have an unlimited number of events

8 Pediatric Adverse Events: Budesonide 11/12/02 – 12/12/03 Relationship of seizures (6) to budesonide not clear –1 case confounded by use of theophylline –2 cases not confirmed by health care professional; seizures not well described –1 patient received CNS radiotherapy, stem cell transplantation, concomitant use of drug labeled for seizures –1 case temporally related, no known confounding –1 case of seizure a/w adrenal suppression

9 Pediatric Adverse Events: Budesonide 11/12/02 – 12/12/03 Systemic steroid effects (n=17) Growth retardation-4 Blood Cortisol Decreased-3 Adrenal Suppression-2 Cataract Bilateral Nos-2 Cushing’s Syndrome-2 Cushingoid-2 Pituitary-Dependent Cushing’s Syndrome-2 Diabetes, hyperglycemia, hypertension, pancreatitis (1 case each)

10 Pediatric Adverse Events: Death US case. A 3-year-old girl who had received Pulmicort Respules for 3 months at an unknown dose for an unknown indication stopped breathing and was transported to an emergency room. The patient was receiving albuterol, cetirizine, cefdinir, and loratadine, and 2 other unknown medications concomitantly. The patient died in the emergency room. An autopsy showed mild pulmonary edema, congestion, and intra-alveolar hemorrhage, but the autopsy did not establish the cause of death.

11 Conclusions on Pediatric Adverse Events: Budesonide 11/12/02 – 12/12/03 Most events, including systemic steroid effects, are included in labeling Convulsions not labeled, unclear relationship to budesonide

12

13 Fluticasone

14 Drug Use Trends in Outpatient Settings: Fluticasone Topical Ointment/Cream The total number of prescriptions dispensed for fluticasone topical ointment/cream in the U.S. have decreased by 17.5% in the past 2 years (3/02 to 2/04), from 1.2 million in 2002 to 990,000 in In the outpatient setting, children and adolescents have accounted for ~ 34% of all fluticasone topical ointment/cream prescriptions over the past two years (3/02-2/04) 2 1 IMS Health, National Prescription Audit Plus , On-Line, Mar 2001 – Feb 2004, Data Extracted Jul AdvancePCS  Dimension Rx, On-Line, Mar 2001 – Feb 2004, Data Extracted Jul 2004

15 Drug Use Trends in Outpatient Settings: Fluticasone Nasal Spray The total number of prescriptions dispensed for fluticasone nasal spray in the U.S. have remained fairly consistent during the past 2 years (3/02 to 2/04), from 13.4 million in 2002 to 15.3 million in Top three prescribers in 2003 were: family practice, internal medicine, and osteopathic medicine. 1 1 IMS Health, National Prescription Audit Plus , On-Line, Mar 2001 – Feb 2004, Data Extracted May 2004

16 Drug Use Trends in Outpatient Settings: Fluticasone Nasal Spray In the outpatient setting, children and adolescents have accounted for approximately 9% of all fluticasone nasal spray prescriptions over the past two years (3/02-2/04) 2 –1.2 million prescriptions (9 %) (March 2002-February 2003) 1,2* –1.4 million prescriptions (9%) (March 2003-February 2004) 1,2* The most common diagnosis associated with the mention of fluticasone nasal spray was seasonal allergic rhinitis in patients 0-16 years. 3 1 IMS Health, National Prescription Audit Plus , On-Line, Mar 2001 – Feb 2004, Data Extracted May AdvancePCS  Dimension Rx, On-Line, Mar 2001 – Feb 2004, Data Extracted May IMS Health, National Disease and Therapeutic Index , CD-Rom, Mar Feb 2004, Data Extracted May 2004 *Calculation based on application of proportions of pediatric fluticasone prescription claims in AdvancePCS  to total number of prescriptions dispensed in IMS Health, National Prescription Audit Plus  to estimate number of fluticasone prescriptions dispensed nationwide to pediatric population.

17 Drug Use Trends in Outpatient Settings: Fluticasone Oral Inhaler The total number of prescriptions dispensed for fluticasone oral inhaler in the U.S. have decreased during the past 2 years (3/02 to 2/04), from 7.9 million in 2002 to 6.9 million in Top three prescribers in 2003 were: internal medicine, family practice, and pediatrics. 1 1 IMS Health, National Prescription Audit Plus , On-Line, Mar 2001 – Feb 2004, Data Extracted May 2004

18 Drug Use Trends in Outpatient Settings: Fluticasone Oral Inhaler In the outpatient setting, children and adolescents have accounted for over 24% of all fluticasone oral inhaler prescriptions over the past two years (3/02-2/04) 2 –1.9 million prescriptions (24%) (March 2002-February 2003) 1,2* –1.9 million prescriptions (28%) (March 2003-February 2004) 1,2* The most common diagnosis associated with the mention of fluticasone oral inhaler was bronchial asthma. 3 1 IMS Health, National Prescription Audit Plus , On-Line, Mar 2001 – Feb 2004, Data Extracted May AdvancePCS  Dimension Rx, On-Line, Mar 2001 – Feb 2004, Data Extracted May IMS Health, National Disease and Therapeutic Index , CD-Rom, Mar Feb 2004, Data Extracted May 2004 *Calculation based on application of proportions of pediatric fluticasone prescription claims in AdvancePCS  to total number of prescriptions dispensed in IMS Health, National Prescription Audit Plus  to estimate number of fluticasone prescriptions dispensed nationwide to pediatric population.

19 Drug Use Trends in Outpatient Settings: Advair (fluticasone & salmeterol combination) Prescriptions dispensed rose from 3.7 million in 2001 to 15.5 million in Advair accounted for 17% of orally inhaled steroid Rx in 2001 and 54% in Age 2-16 ~ 13% of total claims 1,2* 1 IMS Health, National Prescription Audit Plus , On-Line, Mar 2001 – Feb 2004, Data Extracted May AdvancePCS  Dimension Rx, On-Line, Mar 2001 – Feb 2004, Data Extracted May 2004 *Calculation based on application of proportions of pediatric desloratadine prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of desloratadine prescriptions dispensed nationwide to pediatric population

20 Adverse Event Reports: Fluticasone From Marketing Approval (10/19/94 – 3/25/04) –Total number of reports, all ages: 4651 reports (3550 US) From One-Year Post Exclusivity (2/25/03 – 3/25/03) –Total number of reports, all ages: 2093 reports (1904 US) –1240 serious (331 US) –Pediatric Reports: 128 reports (105 US) –29 serious (16 US) –5 death (4 US)

21 Pediatric Adverse Events: Fluticasone 2/25/03 – 3/25/04 (n=128) Gender –Female59 –Male67 –Unknown2 Age –0 - <1 mo.0 –1 mo. - <2 yrs1 –2 - 5 yrs26 –6-11 yrs68 –12-16 yrs32 Products –Inhaled fluticasone22 –Nasal24 –Inhaled fluticasone in combination /w salmeterol82

22 Pediatric Adverse Events: Fluticasone (n=128) Asthma—15 Vomiting—11 Dyspnoea—9 Drug Ineffective—8 Pharmaceutical Product Complaint—8 Condition aggravated—6 Cough—6 Pyrexia—6 Nausea—5 Cardiac Arrest—4 Growth Retardation—4 Headache—4 Loss of Consciousness—4 Rash—4 Weight Increased—4

23 Issues from Pediatric Adverse Events: Fluticasone 2/25/03 – 3/25/04 Systemic steroid effects –12 cases (1 death) Worsening asthma symptoms with Advair: –22 cases (4 deaths)

24 Issues from Pediatric Adverse Events: Fluticasone 2/25/03 – 3/25/04 Systemic steroid effects –12 cases (1 death) Worsening asthma symptoms with Advair: –22 cases (4 deaths)

25 Pediatric Adverse Events: Fluticasone Worsening asthma symptoms with Advair (n=22) –Serious outcomes-10 Death-4 –Age 5-14 years –Race not reported in most cases –Time to onset 0 days to 2 years (median 21 days) –Relative contribution of underlying disease & Advair not known

26 Pediatric Adverse Events: Deaths 1. US case. A 14-year-old black male was prescribed Advair after an episode of respiratory arrest. He had received Advair Diskus for 2 years when he experienced an acute asthma attack. He was transported to an emergency room; when he arrived he was in full cardiac arrest, and he died. No autopsy was performed.

27 Pediatric Adverse Events: Deaths 2. US case. A 13-year-old white male who had received Advair for about 6 months experienced an asthma attack, and he died. The treating physician stated the death was not due to Advair. An autopsy showed chronic bronchitis, hypertrophy of bronchial muscle, infiltrate of eos, mucous plugging of smaller bronchi/bronchioles, scattered microscopic foci of acute pneumonia, organizing pneumonia, and air trapping in the alveoli.

28 Pediatric Adverse Events: Deaths 3. Non-US case. A 14-year-old asthmatic girl was treated with salmeterol for an acute asthma attack. Apparently the patient refused treatment with a systemic corticosteroid. When she did not respond in the first day to treatment with salmeterol, treatment with a combined salmeterol and fluticasone product was started. Additionally, the patient was receiving albuterol. About 2 hours after her first dose of the combination product, the patient’s condition worsened. She developed circulatory failure, and she died despite attempts to resuscitate her.

29 Pediatric Adverse Events: Deaths 4. US case. A 13-year-old boy experienced cardiac arrest and died after receiving Advair for an unknown period of time. While talking to a friend on the phone, the boy “just stopped talking.” An autopsy showed only lungs changes consistent with asthma.

30 Pediatric Adverse Events: Fluticasone 2/25/03 – 3/25/04 (n=128) Gender –Female59 –Male67 –Unknown2 Age –0 - <1 mo.0 –1 mo. - <2 yrs1 –2 - 5 yrs26 –6-11 yrs68 –12-16 yrs32 Products –Inhaled fluticasone22 –Nasal24 –Inhaled fluticasone in combination /w salmeterol82

31 Pediatric Advair AERS Reports 10/00 – 3/04

32 Relevant Safety Labeling

33

34 Issues from Pediatric Adverse Events: Fluticasone 2/25/03 – 3/25/04 Systemic steroid effects –12 cases (1 death) Worsening asthma symptoms with Advair: –22 cases (4 deaths)

35 Pediatric Adverse Events: Fluticasone Systemic steroid effects (n=12) –Products/Doses Nasal product-2 Inhaled product-9 More than 1 source of steroids-6 Dose not reported in 4 cases Only 1 case reported effect (GR) w/ Flonase w/i labeled dose

36 Pediatric Adverse Events: Deaths 1. Non-US case. An 8-year-old girl who used inhaled fluticasone for an unknown indication at an unknown dose for an unknown period of time developed adrenal crisis, and she died. Details regarding the case were not reported.

37 Conclusions on Pediatric Adverse Events: Fluticasone 2/25/03 – 3/25/04 Most events, including systemic steroid effects, are included in labeling Relative contribution of underlying disease & Advair in the AERS cases of asthma exacerbation not known Advair labeling contains warning about asthma outcomes with salmeterol